Accurate dosimetry in 131I radionuclide therapy using patient-specific, 3-dimensional methods for SPECT reconstruction and absorbed dose calculation

被引:0
|
作者
Dewaraja, YK
Wilderman, SJ
Ljungberg, M
Koral, KF
Zasadny, K
Kaminiski, MS
机构
[1] Univ Michigan, Med Ctr, Dept Radiol, Div Nucl Med, Ann Arbor, MI 48109 USA
[2] Lund Univ, Dept Med Radiat Phys, S-22100 Lund, Sweden
[3] Pfizer Global Res & Dev, Ann Arbor, MI USA
[4] Univ Michigan, Med Ctr, Dept Internal Med, Div Hematol & Oncol, Ann Arbor, MI 48109 USA
关键词
3-dimensional dosimetry; radioimmunotherapy; SPECT; Monte Carlo dosimetry; I-131;
D O I
暂无
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
I-131 radionuclide therapy studies have not shown a strong relationship between tumor absorbed dose and response, possibly due to inaccuracies in activity quantification and dose estimation. The goal of this work was to establish the accuracy of I-131 activity quantification and absorbed dose estimation when patient-specific, 3-dimensional (3D) methods are used for SPECT reconstruction and for absorbed dose calculation. Methods: Clinically realistic voxel-phantom simulations were used in the evaluation of activity quantification and dosimetry. SPECT reconstruction was performed using an ordered-subsets expectation maximization (OSEM) algorithm with compensation for scatter, attenuation, and 3D detector response. Based on the SPECT image and a patient-specific density map derived from CT, 3D dosimetry was performed using a newly implemented Monte Carlo code. Dosimetry was evaluated by comparing mean absorbed dose estimates calculated directly from the defined phantom activity map with those calculated from the SPECT image of the phantom. Finally, the 3D methods were applied to a radioimmunotherapy patient, and the mean tumor absorbed dose from the new calculation was compared with that from conventional dosimetry obtained from conjugate-view imaging. Results: Overall, the accuracy of the SPECT-based absorbed dose estimates in the phantom was > 12% for targets down to 16 mL and up to 35% for the smallest 7-mL tumor. To improve accuracy in the smallest tumor, more OSEM iterations may be needed. The relative SD from multiple realizations was < 3% for all targets except for the smallest tumor. For the patient, the mean tumor absorbed dose estimate from the new Monte Carlo calculation was 7% higher than that from conventional dosimetry. Conclusion: For target sizes down to 16 mL, highly accurate and precise dosimetry can be obtained with 3D methods for SPECT reconstruction and absorbed dose estimation. In the future, these methods can be applied to patients to potentially establish correlations between tumor regression and the absorbed dose statistics from 3D dosimetry.
引用
收藏
页码:840 / 849
页数:10
相关论文
共 33 条
  • [1] A 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy:: Evaluation for 131I using Monte Carlo simulation
    Ljungberg, M
    Sjögreen, K
    Liu, XW
    Frey, E
    Dewaraja, Y
    Strand, SE
    JOURNAL OF NUCLEAR MEDICINE, 2002, 43 (08) : 1101 - 1109
  • [2] MIRD Pamphlet No. 23: Quantitative SPECT for Patient-Specific 3-Dimensional Dosimetry in Internal Radionuclide Therapy
    Dewaraja, Yuni K.
    Frey, Eric C.
    Sgouros, George
    Brill, A. Bertrand
    Roberson, Peter
    Zanzonico, Pat B.
    Ljungberg, Michael
    JOURNAL OF NUCLEAR MEDICINE, 2012, 53 (08) : 1310 - 1325
  • [3] RMDP:: A dedicated package for 131I SPECT quantification, registration and patient-specific dosimetry
    Guy, MJ
    Flux, GD
    Papavasileiou, P
    Flower, MA
    Ott, RJ
    CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS, 2003, 18 (01) : 61 - 69
  • [4] Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software
    Sgouros, G
    Kolbert, KS
    Sheikh, A
    Pentlow, KS
    Mun, EF
    Barth, A
    Robbins, RJ
    Larson, SM
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (08) : 1366 - 1372
  • [5] Spatiotemporal dose distribution for patient-specific bioeffect modeling using hybrid SPECT-Planar imaging of 131I Radiopharmaceutical Therapy
    Shin, Jungwook
    Seo, Youngho
    Flavell, Robert
    Rafet, Sergio
    Yeom, Yeon Soo
    Kitahara, Cari
    Lee, Choonsik
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [6] NRC absorbed dose reconstruction for family member of 131I therapy patient:: Case study and commentary
    Marcus, CS
    Siegel, JA
    JOURNAL OF NUCLEAR MEDICINE, 2004, 45 (04) : 13N - +
  • [7] ACCURATE 3-DIMENSIONAL DOSE CALCULATION USING A QUANTITATIVE SPECT IMAGE FOR RADIOIMMUNOTHERAPY
    OGAWA, K
    KANBE, N
    UCHIDA, I
    YAMADA, Y
    ITOH, A
    AKIYAMA, Y
    JOURNAL OF NUCLEAR MEDICINE, 1994, 35 (05) : P160 - P161
  • [8] Methodology to Incorporate Biologically Effective Dose and Equivalent Uniform Dose in Patient-Specific 3-Dimensional Dosimetry for Non-Hodgkin Lymphoma Patients Targeted with 131I-Tositumomab Therapy
    Amro, Hanan
    Wilderman, Scott J.
    Dewaraja, Yuni K.
    Roberson, Peter L.
    JOURNAL OF NUCLEAR MEDICINE, 2010, 51 (04) : 654 - 659
  • [9] Prediction of absorbed dose to normal organs in thyroid cancer patients treated with 131I by use of 124I PET and 3-dimensional internal dosimetry software
    Kolbert, Katherine S.
    Pentlow, Keith S.
    Pearson, Joel R.
    Sheikh, Arif
    Finn, Ronald D.
    Humm, John L.
    Larson, Steven M.
    JOURNAL OF NUCLEAR MEDICINE, 2007, 48 (01) : 143 - 149
  • [10] Evaluation and validation of GATE-based absorbed dose calculation for 3D patient-specific internal dosimetry
    Williams, C.
    Burckhardt, D.
    Engdahl, J.
    MEDICAL PHYSICS, 2006, 33 (06) : 2098 - 2098